Cancer Research Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J. M.
Right arrow Articles by Grupp, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J. M.
Right arrow Articles by Grupp, S. A.
[Cancer Research 62, 4212-4216, August 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Cytoplasmic µ Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia1

Jenny M. Kim, Junjie Fang, Susan Rheingold, Richard Aplenc, Robert Wasserman and Stephan A. Grupp2

Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [J. M. K., J. F., S. R., R. A., S. A. G.]; University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 [S. R., R. A., S. A. G.]; and Merck Research Laboratories, West Point, Pennsylvania 19486 [R. W.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Most childhood acute lymphoblastic leukemia (ALL) arises from early B-lineage cells,and response to steroid treatment is critical to successful ALL therapy.To investigate the effect of the pre-B cell receptor (pre-BCR) complex on the response of leukemic cells to steroids, cytoplasmic µ protein (cyto µ) was transfected into cyto µ-, steroid-resistant early B cell lines. The presence of cyto µ and the assembled pre-BCR complex conferred sensitivity to dexamethasone-induced apoptosis. Both intrinsic and extrinsic apoptosis pathways are involved in this cell death. However, if the transfected cyto µ protein is unable to assemble the pre-BCR complex, the cells remain resistant to dexamethasone. These findings suggest a role for the pre-BCR complex in the response of ALL cells to treatment and provide insight into the mechanism of steroid response in the treatment of pre-B ALL.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Approximately 75% of childhood ALL3 results from transformation events that occur in early B-lineage cells (1) . Advances in understanding the stages of B cell ontogeny and the signaling pathways driving B cell development offer the opportunity to better characterize the biology of ALL and the mechanisms of treatment response. The key control point during normal B cell development comes at the transition from the pro-B through the pre-B stage. Cytoplasmic expression of intact IgM heavy chain protein (cyto µ) and assembly of the pre-BCR complex defines this stage of development (2 , 3) . The pre-BCR complex consists of µ heavy chain, surrogate light chain, and the Ig{alpha}/ß heterodimer. Ig{alpha}/ß serves as the signal transduction unit of the complex (3) . Apoptotic signals as well as growth and survival signals work together to maintain B-lymphocyte homeostasis, delete the vast majority of B cells that fail to form an intact antigen receptor, and result in a functional humoral immune system (2) . Because the pre-BCR complex is an important checkpoint at this stage of B cell development, we hypothesized that signaling through the pre-BCR complex would influence the response of early B-lineage cells to chemotherapy.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Cell Lines.
Two early B-lineage cell lines were used in these studies. NFS-70 (American Type Culture Collection, Manassas, VA) is a pro-B cell murine lymphoblast line (B220/CD45R+ CD5+ CD32+ cyto µ-; Ref. 4 ). ret02/1 is also a pro-B murine lymphoblast line (B220/CD45R+ CD43+ cyto µ-; Ref. 5 ). Jurkat cells (human T-cell leukemia line; American Type Culture Collection) were used as a control cell line for the apoptosis assays. The cells were maintained in RPMI 1640 with L-glutamine (Invitrogen Corp., Carlsbad, CA), 10 mM HEPES, 1 mM sodium pyruvate, 100 µM non-essential amino acids, penicillin 100 units/ml, streptomycin 100 µg/ml, and 10% FCS (C10 medium).

Transfection with Human µ Constructs.
The ret02/1 and NFS-70 parent cell lines were transfected by electroporation (3) with a human µ construct containing the rearranged variable region of S107, a phosphorylcholine-specific murine IgM, and the human IgM constant region. These constructs have been described previously (3 , 6) . The cDNA sequence encoded either wild-type µ heavy chain or a mutant form with a 2-amino acid transmembrane region substitution (Y587/S588->V/V) referred to as {Delta}µ. This substitution prevents the association of the Ig{alpha}/ß heterodimer to the pre-BCR complex,4 thus eliminating the {Delta}µ signal transduction (3 , 6) . The NFS-70 cell line was cotransfected with a plasmid containing the S107{kappa} coding sequence and the neomycin resistance gene (neo). The ret02/1 cells were cotransfected with a neo-containing plasmid (pcDNA 3.1; Invitrogen) only. The presence of the transfected cDNA was verified by PCR for heavy and light chain-specific sequences. Using forward primer 5'-AAGGGTGGGCCTAGAGGAT-3' and reverse primer 5'-CACCTACAGGCAACAGAGA-3', we were able to amplify a 300-bp fragment in the transmembrane coding region of µ heavy chain. Transfection of µ or {Delta}µ was confirmed by sequencing this PCR product that included the relevant portion of the transmembrane coding sequence. Translation of µ protein was verified by flow cytometry as well as immunoblot.

Western Blot and Immunoprecipitation.
Equal numbers of cells were lysed with 1% Triton X-100 (Sigma, St. Louis, MO) plus protease inhibitors. To confirm equal total protein in the lysates before immunoprecipitation, protein concentrations of lysates were quantitated using the Bradford technique. Transfected µ protein was immunoprecipitated with rabbit anti-human IgM antibody (Jackson ImmunoResearch, West Grove PA) and protein A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz CA). Murine Bcl-2 protein was immunoprecipitated with anti-Bcl-2 antibody-conjugated agarose beads (Santa Cruz Biotechnology). Murine Bax protein was immunoprecipitated by rabbit anti-Bax IgG (Upstate Biotechnology, Lake Placid, NY) and protein G agarose beads (Invitrogen). Specific proteins were detected on polyvinylidene difluoride membranes using horseradish peroxidase-conjugated anti-human IgM (Jackson ImmunoResearch) or horseradish peroxidase-conjugated anti-Bcl-2 or anti-Bax (Santa Cruz Biotechnology) antibodies and developed with enhanced chemiluminescence reagent (Amersham Biosciences, Piscataway, NJ). The protein bands were quantitated from the film by densitometry using NIH Image (Scion Corporation, Frederick, MD).

Flow-cytometric Analyses.
Surface IgM was detected on intact cells using FITC-conjugated anti-human IgM and anti-mouse IgM polyclonal antibodies (Jackson ImmunoResearch). Cytoplasmic µ was detected in permeabilized cells using the same antibodies. FITC-conjugated IgG of the same species was used to measure nonspecific labeling. Viable FITC-Annexin V and paraformaldehyde-fixed TUNEL-labeled cells were also analyzed by flow cytometry. Fluorescence intensity of labeled cells was measured using a FACScan cytometer (BD Biosciences, Franklin Lakes, NJ).

Apoptosis Assays.
Viable cells were counted by trypan blue and plated at 0.5–1 x 105 cells/ml in C10 medium. The cells were then incubated with 0.1–10 µM dex (Sigma) or 1–2 µg/ml anti-fas antibody (R&D Systems, Minneapolis, MN) for 12–65 h. For the apoptosis inhibition assays, the cells were incubated with dex or anti-fas antibody and with 50 µM pancaspase inhibitor z-VAD-fmk (Calbiochem, San Diego, CA). Levels of exposed phosphatidylserine on viable cells were measured using the ApoAlert Annexin V detection kit (Clontech, Palo Alto, CA). Cells were incubated with FITC-conjugated Annexin V, and log fluorescence intensity was analyzed by flow cytometry.

DNA nicks created by endonucleases during initiation of apoptosis were detected by TUNEL assay (Apoptosis Detection System; Promega, Madison, WI). The cells were fixed with 1–2% paraformaldehyde and permeabilized with 0.2% Triton X-100. Cells were labeled with FITC-conjugated dUTP and terminal deoxynucleotidyltransferase enzyme. Nicked DNA labeled with FITC-dUTP was detected by flow cytometry.

Fragmented DNA was detected in treated cells using the Apoptotic DNA Ladder Kit (Roche Molecular Biochemicals, Indianapolis, IN). A positive control (apoptotic U937 cells) was also provided in the kit. The DNA was isolated and run on a 1% agarose gel with ethidium bromide.

Detection of Activated Caspases.
CaspaTag 8 (carboxyfluorescein benzyloxycarbonyl leucylglutamylthreonylaspartic acid fluoromethyl ketone [FAM-LETD-fmk]; Serologicals Corp., Purchase, NY) is a carboxyfluorescein derivative of the inhibitor of caspase 8. CaspaTag 9 (carboxyfluorescein benzyloxycarbonyl leucylglutamylhistidylaspartic acid fluoromethyl ketone [FAM-LEHD-fmk]; Intergen, Purchase NY) is a carboxyfluorescein derivative of the inhibitor of caspase 9. Lyophilized CaspaTag 8 and 9 were reconstituted in DMSO at 150x and diluted to 30x with PBS just before use. The cells were incubated with CaspaTag 8 or 9 and then analyzed immediately by flow cytometry.

Statistics.
STATA 7.0 (Stata Corporation, College Park, TX) was used for all statistical analysis. Paired and unpaired t tests with unequal variances were used to compare apoptotic indices within and between cell lines. The rate of change in apoptosis over time and area under the dose-response curve were estimated by STATA functions. These values were compared between cell lines with t tests with unequal variances. All Ps were two sided and 0.05 was used as the level of significance.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Cytoplasmic µ Heavy Chain Transfected into Early B-lineage ALL Cell Lines Confers Sensitivity to dex-induced Apoptosis.
To examine the role of µ heavy chain protein in the response of pre-B cells to steroids, we transfected cyto µ-negative, murine pro-B cell lines with a µ construct that directs the synthesis of a membrane-bound form of µ protein. Western analysis verified the presence of µ protein in the transfected cells, and there was no detectable expression of IgM on the cell surface (not shown). However, µ protein was detected intracellularly after transfected cells were permeabilized (not shown). To assess the requirement for the assembly of the complete pre-BCR signaling complex, we transfected the same pro-B cell lines with the signal-impaired {Delta}µ construct, which does not assemble the pre-BCR complex (3) . The presence of the appropriate construct (µ versus {Delta}µ) was verified by sequencing of a PCR product that amplified the coding sequence of the transmembrane region.

We then treated our transfected and parent cell lines with 1 µM dex for 48–60 h and labeled them with Annexin V-FITC or by TUNEL, or detected fragmented DNA ladders to identify cells undergoing apoptosis. Representative flow histograms of Annexin V assays are shown in Fig. 1, A and BCitation . The untreated ret02/1 parent cells and the µ- and {Delta}µ-transfected cells were not apoptotic and showed lack of Annexin V labeling. However, expression of µ in the context of an intact pre-B cell receptor complex (ret/µ) conferred sensitivity to dex. In Fig. 1ACitation , 92% of µ-transfected cells treated with 1 µM dex for 60 h were apoptotic as shown by labeling with Annexin V. However, expression of µ protein without assembly of the pre-BCR complex (ret/{Delta}µ) did not change the sensitivity of these pro-B cell lines to dex, and the lack of apoptotic response to dex was identical to that seen in the parent cell line (Fig. 1A)Citation . Treatment with anti-fas antibody had no effect on the ret02/1, ret/µ, and ret/{Delta}µ cells (not shown).



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Transfected cyto µ heavy chain confers sensitivity to dex-induced apoptosis in early B cell lines. Two different parent early B cell lines and µ- or {Delta}µ-transfected cell lines were treated with 1 µM dex for 60 h and then labeled with Annexin V. Flow-cytometric histograms are shown: A, dex-treated ret02/1 parent pro-B cells, µ-transfected (ret/µ) ret cells, and {Delta}µ-transfected (ret/{Delta}µ) ret cells; B, dex-treated NFS-70 parent cells, µ-transfected (NFS/µ) NFS-70 cells, and {Delta}µ-transfected (NFS/{Delta}µ) NFS-70 cells. ret02/1, ret/µ, and ret/{Delta}µ cells (C) treated with 10 µM dex and analyzed at multiple time points (D) were treated with various concentrations of dex and analyzed after 65 h of treatment. Annexin V labeling was measured by flow cytometry.

 
To confirm the effect of pre-BCR expression on dex sensitivity in early B cell lines, we repeated these experiments using the pro-B cell line NFS-70. Similar results were seen with NFS-70 parent and transfected NFS-70 cells treated with 1 µM dex for 60 h (Fig. 1B)Citation . With expression of intact µ (NFS/µ), dex-resistant NFS-70 cells became apoptotic in response to dex. The parent NFS-70 and NFS/{Delta}µ cells showed minimal apoptotic response to dex.

Time course and dose-response curves for dex apoptosis assays performed in triplicate are shown in Fig. 1, C and DCitation , respectively. ret02/1, ret/{Delta}µ, and ret/µ cells were treated with dex at concentrations of 0.1, 1, and 10 µM dex and evaluated after 24, 48, and 65 h of treatment. The time course for 10 µM dex treatment is shown in Fig. 1CCitation . ret/µ-transfected cells showed significantly greater apoptosis in response to dex over time (versus ret02/1, P = 0.0001; versus ret/{Delta}µ, P = 0.0002). ret02/1 parent cells showed almost no response to dex treatment over time. Like the parent cells, cells transfected with signal-impaired µ ({Delta}µ) also had almost no response to dex up to 65 h of treatment. The dose-response curve at 65 h showed that the ret/µ cells were sensitive to dex doses as low as 0.1 µM, and this apoptotic response was significant (Fig. 1DCitation ; versus ret02/1, P < 0.0001; versus ret/{Delta}µ, P = 0.0002). After 24 h of dex treatment, the parent and {Delta}µ cells showed essentially no (3–7%) apoptotic response with escalating doses of dex. Even at this earlier time point, dex caused cell death in ret/µ cells in a dose-dependent fashion, with apoptosis increasing by 20% with 0.1 µM dex and increasing by 30% with 10 µM dex (not shown). A similar response was seen at 48 h of dex treatment, where we observed a 28% increase in apoptosis with 0.1 µM and a 54% increase with 10 µM dex (not shown).

After treating ret02/1 parent and µ- and {Delta}µ-transfected cells with 1 µM dex for 48 h, the characteristic apoptotic DNA ladder was only detected in ret/µ cells treated with dex (Fig. 2A)Citation . DNA from the dex-treated parent and {Delta}µ-transfected cells was unchanged from the DNA of the untreated controls. When apoptosis was measured by TUNEL (Fig. 2B)Citation , 92% of µ-transfected cells were apoptotic after treatment with 1 µM dex for 48 h. No appreciable TUNEL response was seen in parent or {Delta}µ cells treated with dex (not shown).



View larger version (73K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Dex-induced apoptosis in cyto µ-transfected early B cells is detected by apoptotic DNA ladder and TUNEL and is partially blocked by pancaspase inhibitor z-VAD-fmk. A, ret02/1, ret/µ, and ret/{Delta}µ cells were either untreated (-) or treated with 1 µM dex for 48 h (+). DNA was isolated, and DNA laddering was visualized on an ethidium bromide/agarose gel. B–D, µ-transfected ret cells were treated with 1 µM dex ± 50 µM pancaspase inhibitor z-VAD-fmk for 60 h and then labeled by TUNEL. Cells were analyzed by flow cytometry, and apoptosis is indicated by increase in log fluorescence intensity. B, untreated cells; C, dex-treated cells; D, cells treated with dex and z-VAD-fmk.

 
Pancaspase Inhibitor Partially Blocks dex-induced Apoptosis in Cell Lines Transfected with Cytoplasmic µ Protein.
To investigate possible mechanisms of dex-induced cell death in µ-transfected early B cells, we explored the caspase pathways. z-VAD-fmk is an irreversible pancaspase inhibitor that binds to and inhibits activated caspases-1 through -9. µ-transfected cell lines treated with dex and z-VAD-fmk for 60 h showed 41% inhibition of apoptosis as shown by TUNEL, compared with treatment with dex alone (Fig. 2B)Citation . There was no effect of the pancaspase inhibitor on the parent cell lines or on the {Delta}µ-transfected cells. As a control experiment, inhibition of apoptosis was also seen in Jurkat cells treated with anti-fas antibody and z-VAD-fmk (not shown).

Activated Caspases 8 and 9 Are Involved in dex-induced Apoptosis.
Caspases 8 and 9 are key initiators in extrinsic and intrinsic pathways of apoptosis, respectively, although there can be cross-talk and amplification between the two pathways (7) . Using carboxyfluorescein-labeled specific caspase inhibitors that bind to active caspases 8 and 9 (CaspaTag 8 and 9), both activated caspases 8 and 9 were detected in µ-transfected cells treated with dex. Untreated cells showed <12% of cells expressing activated caspase 9 (Fig. 3A)Citation . Activated caspase 8 was also low in these untreated cells (not shown). After treatment with dex, 67% of µ-transfected ret cells had detectable levels of activated caspase 8 enzyme and 63% had activated caspase 9 (Fig. 3, B and C)Citation . Dex-treated ret02/1 parent cells and ret/{Delta}µ-transfected cells showed minimal activation of caspase 8 or 9 (Fig. 3, D–I)Citation . A positive control was established using Jurkat cells treated with anti-fas antibody. Jurkat cells are known to activate caspase 8 and 9 and undergo programmed cell death after ligation of fas (8) , and >50% of anti-fas antibody-treated Jurkat cells showed the presence of active caspases 8 and 9 (not shown).



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Activated caspases 8 and 9 are detected in cyto µ-transfected early B cells treated with dex. ret02/1, ret/µ, and ret/{Delta}µ cells were incubated with 1 µM dex. CaspaTag labeling was analyzed by flow cytometry. Activated caspase 9 was assessed in untreated ret/µ (A), ret02/1 (D), and ret/{Delta}µ (G) cells. Activated caspase 8 was assessed in dex-treated (+ DEX) ret/µ (B), ret02/1 (E), and ret/{Delta}µ (H) cells. Activated caspase 9 was assessed in dex-treated (+ DEX) ret/µ (C), ret02/1 (F), and ret/{Delta}µ (I) cells.

 
Bcl-2 Protein Is Down-regulated but Bax Levels Remain Unchanged during dex-induced Apoptosis.
To assess further the apoptotic effects of dex, Bcl-2 and Bax protein levels were evaluated by immunoprecipitation and Western blot in untreated and dex-treated cells. ret and {Delta}µ cells showed no change in Bcl-2 protein levels after treatment with dex (Fig. 4A)Citation . However, there was a 2-fold decrease in Bcl-2 protein in µ-transfected cells after 60 h of treatment with 1 µM dex (Fig. 4A)Citation , as shown by immunoblot. Total cellular Bax levels remained unchanged in the µ-transfected, apoptotic cells after treatment with dex (Fig. 4B)Citation .



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Bcl-2 protein decreases 2-fold in µ-transfected cells, whereas Bax protein levels remain unchanged after treatment with dex. Immunoprecipitation from equal amounts of crude lysate proteins and Western blot showing Bcl-2 protein levels in ret02/1, µ, and {Delta}µ cells untreated and after treatment with dex (A) and Bax protein levels in µ-transfected cells untreated and after treatment with dex (B).

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Early B-lineage ("pre-B") cell ALL is the most common immunophenotype in childhood ALL and is known to respond well to chemotherapy (1) . Steroids are a major part of both induction and maintenance therapy for ALL, and the initial response of ALL to steroid treatment is an established prognostic variable (9 , 10) . We demonstrate three significant findings which establish a role for pre-BCR complex-mediated signaling in the apoptotic response of early B cell ALL lines to steroid treatment. (a) Steroid-resistant, cyto µ-negative early B cell lines transfected with µ protein become sensitive to dex-induced cell death in both a dose- and time-dependent manner. (b) µ, in the absence of the pre-BCR signaling complex, does not confer apoptotic sensitivity to steroid treatment. These findings indicate that both cyto µ- and Ig{alpha}/ß-mediated signaling are involved in facilitating the apoptotic response to dex. (c) Both intrinsic and extrinsic pathways of apoptotic signaling are involved in this model of dex-induced apoptosis in early B-lineage lymphoblasts. Caspases 8 and 9 are activated in this apoptotic pathway as a result of dex treatment. Other factors independent of the caspases must also be involved because caspase inhibition does not fully reverse the apoptotic response.

Here, we show that treating cyto µ-transfected cells with dex results in activation of both caspases 8 and 9. Treatment with anti-fas antibodies had no effect on these cells. Early B-lineage cells are not known to have tumor necrosis factor family receptors with death domains on their cell surface. The pathway(s) by which caspase 8 might be activated in cyto µ-transfected cells is not clear. However, intracellular mechanisms bridging extrinsic and intrinsic apoptotic pathways do exist (7 , 11) .

Expression of Bcl-2 family members in acute lymphoblastic leukemias has been described (12, 13, 14) . Because Bcl-2 promotes cell survival, one might expect high levels of Bcl-2 to be associated with poor response to therapy and poorer outcome. However, one study looked at 338 children with ALL and found that, in general, high levels of Bcl-2 expression did not predict slow early response, failure to achieve remission, or poor event-free survival (13) . Another study suggested that Bcl-2 may protect pre-B cells from glucocorticoid-induced apoptosis, even in the face of c-myc repression (15) . In our model, Bcl-2 protein was down-regulated in µ-transfected cells that underwent apoptosis after treatment with dex, but other proapoptotic mechanisms are most likely also involved. In our apoptotic cells, there was not an increase in Bax protein expression; however, we cannot exclude that Bax has translocated to the mitochondrion.

Glucocorticoid-associated new protein expression may result in the activation of tyrosine kinases that can transmit signals linking the pre-BCR complex to the apoptotic machinery, or the presence of the pre-BCR complex may provide a signaling milieu in which the dex response is possible. B cell receptor (BCR)-mediated apoptosis has been described in immature and mature B cells (16) . Signaling events after BCR ligation include phosphorylation of the immunoreceptor tyrosine-based activation motifs in the Ig{alpha}/Igß heterodimer that initiate downstream events leading to activation or apoptosis (17) . Proto-oncogene c-Myc is reported to be enhanced after BCR ligation resulting in mitochondrial dysfunction and apoptosis (16) . Our data do not suggest that actual ligation of the pre-BCR is required for the apoptotic signaling in pre-B cells in response to dex. The pre-BCR may indeed not need a ligand, as its purpose in B cell development is to indicate that an intact cyto µ protein capable of assembling the BCR complex has been expressed. Additional studies will be required to determine the mechanism(s) by which cyto µ and the pre-BCR complex participate in the apoptotic pathway.

The effect of cyto µ on event-free survival was examined in the Pediatric Oncology Group 8602 study. In this study, the presence of cyto µ in the diagnostic lymphoblasts was determined, and patients were stratified according to "pre-B" (cyto µ+) versus "early pre-B" (cyto µ-) phenotype. There was no difference in outcome between the pre-B and early pre-B patients, either as a whole or when stratified by risk group and treatment (18) . Early response to induction therapy was not reported for these patients, so that detecting an association between rapid early response and cyto µ expression was not possible, but would be interesting, given the findings of our study. This similarity in outcome between patients with early pre-B and pre-B phenotypes differed from earlier observations based on less intensive treatment regimens (19) . A recent study in pediatric T-cell ALL reported that in vitro dex-induced apoptosis of primary lymphoblasts correlated with a good in vivo early response to initial therapy by the day-15 bone marrow blast percentage (20) . It is clear that other factors also play a role in therapy response because cyto µ+ ALL accounts for only 20–30% of pre-B ALL (21) , and >90% of children with ALL attain complete remission after induction therapy (which includes other drugs in addition to steroids).

In summary, expression and assembly of cyto µ with the pre-BCR complex is known to be a central regulatory checkpoint in normal B cell development. In the ALL cell lines studied here, the presence of cyto µ and an intact pre-BCR complex confers sensitivity to steroid-induced apoptosis, and this apoptotic signaling involves intrinsic and extrinsic death pathways. Regulation of caspases and Bcl-2 protein plays a role in this cell death signaling. Although patients with cyto µ+ pre-B ALL are a minority of all patients with B-lineage ALL, our data suggest that cyto µ+ lymphoblasts may be more responsive to steroids, leading to the hypothesis that these patients may respond better to the steroid component of their treatment during induction chemotherapy. More importantly, the role of cyto µ and pre-BCR complex signaling in pre-B ALL steroid responsiveness will allow further mechanistic analyses of the response to steroids in the pre-B cell signaling milieu.


   ACKNOWLEDGMENTS
 
We thank Drs. Michael Hogarty and Valerie Brown for helpful advice and comments and Xueyuan Liu and Keith Alcorn for technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by National Institutes of Health Grant 5-T32-CA-09615 (J. M. K.), an American Society of Clinical Oncology Young Investigator Award (J. M. K.), and National Institutes of Health Grant K-K12-CA-76931 (J. M. K.); a Doris Duke Charitable Foundation Clinical Scientist Training Award (R. A.); and National Institutes of Health Grants R01 CA82156 (S. A. G.) and 1R29A140111 (S. A. G.) Back

2 To whom requests for reprints should be addressed, at 902 Abramson Research Center, Children’s Hospital of Philadelphia, 3615 Civic Center Blvd., Philadelphia, PA 19104. E-mail: grupp{at}chop.edu Back

3 The abbreviations used are: ALL, acute lymphoblastic leukemia; pro-B, progenitor-B; pre-B, precursor-B; cyto µ, cytoplasmic µ protein; BCR, B cell receptor; {Delta}µ, µ heavy chain with altered transmembrane domain; z-VAD-fmk, benzyloxycarbonyl valylalanyl aspartic acid fluoromethyl ketone; TUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling; dex, dexamethasone. Back

4 S. R. Rheingold, unpublished data. Back

Received 4/ 8/02. Accepted 6/ 6/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Pui C. H. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr. Opin. Hematol., 5: 292-301, 1998.[Medline]
  2. LeBien T. W. Fates of human B-cell precursors. Blood, 96: 9-23, 2000.[Abstract/Free Full Text]
  3. Cronin F. E., Jiang M., Abbas A. K., Grupp S. A. Role of mu heavy chain in B cell development. I. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta. J. Immunol., 161: 252-259, 1998.[Abstract/Free Full Text]
  4. Davidson W. F., Fredrickson T. N., Rudikoff E. K., Coffman R. L., Hartley J. W., Morse H. C., 3rd. A unique series of lymphomas related to the Ly-1+ lineage of B lymphocyte differentiation. J. Immunol., 133: 744-753, 1984.[Abstract]
  5. Wasserman R., Zeng X. X., Hardy R. R. The evolution of B precursor leukemia in the Emu-ret mouse. Blood, 92: 273-282, 1998.[Abstract/Free Full Text]
  6. Grupp S. A., Campbell K., Mitchell R. N., Cambier J. C., Abbas A. K. Signaling-defective mutants of the B lymphocyte antigen receptor fail to associate with Ig-{alpha} and Ig-ß/{gamma}. J. Biol. Chem., 268: 25776-25779, 1993.[Abstract/Free Full Text]
  7. Kidd V. J., Lahti J. M., Teitz T. Proteolytic regulation of apoptosis. Semin. Cell Dev. Biol., 11: 191-201, 2000.[Medline]
  8. Nagata S. Fas ligand-induced apoptosis. Annu. Rev. Genet., 33: 29-55, 1999.[Medline]
  9. Reiter A., Schrappe M., Ludwig W. D., Hiddemann W., Sauter S., Henze G., Zimmermann M., Lampert F., Havers W., Niethammer D., et al Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood, 84: 3122-3133, 1994.[Abstract/Free Full Text]
  10. Dordelmann M., Reiter A., Borkhardt A., Ludwig W. D., Gotz N., Viehmann S., Gadner H., Riehm H., Schrappe M. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood, 94: 1209-1217, 1999.[Abstract/Free Full Text]
  11. Zhang H., Xu Q., Krajewski S., Krajewska M., Xie Z., Fuess S., Kitada S., Godzik A., Reed J. C. BAR: an apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc. Natl. Acad. Sci. USA, 97: 2597-2602, 2000.[Abstract/Free Full Text]
  12. Jia L., Macey M. G., Yin Y., Newland A. C., Kelsey S. M. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood, 93: 2353-2359, 1999.[Abstract/Free Full Text]
  13. Uckun F. M., Yang Z., Sather H., Steinherz P., Nachman J., Bostrom B., Crotty L., Sarquis M., Ek O., Zeren T., Tubergen D., Reaman G., Gaynon P. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children’s Cancer Group Study. Blood, 89: 3769-3777, 1997.[Abstract/Free Full Text]
  14. Campana D., Coustan-Smith E., Manabe A., Buschle M., Raimondi S. C., Behm F. G., Ashmun R., Arico M., Biondi A., Pui C. H. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood, 81: 1025-1031, 1993.[Abstract/Free Full Text]
  15. Alnemri E. S., Fernandes T. F., Haldar S., Croce C. M., Litwack G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B- leukemias. Cancer Res., 52: 491-495, 1992.[Abstract/Free Full Text]
  16. Tsubata T. Molecular mechanisms for apoptosis induced by signaling through the B cell antigen receptor. Int. Rev. Immunol., 20: 791-803, 2001.[Medline]
  17. Wienands J. Signal transduction elements of the B cell antigen receptor and their role in immunodeficiencies. Immunobiology, 202: 120-133, 2000.[Medline]
  18. Harris M. B., Shuster J. J., Pullen J., Borowitz M. J., Carroll A. J., Beh F. G., Camitta B., Land V. J. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia (Baltimore), 14: 1570-1576, 2000.[Medline]
  19. Crist W. M., Carroll A. J., Shuster J. J., Behm F. G., Whitehead M., Vietti T. J., Look A. T., Mahoney D., Ragab A., Pullen D. J. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood, 76: 117-122, 1990.[Abstract/Free Full Text]
  20. Wuchter C., Ruppert V., Schrappe M., Dorken B., Ludwig W. D., Karawajew L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood, 99: 4109-4115, 2002.[Abstract/Free Full Text]
  21. Uckun F. M., Sensel M. G., Sather H. N., Gaynon P. S., Arthur D. C., Lange B. J., Steinherz P. G., Kraft P., Hutchinson R., Nachman J. B., Reaman G. H., Heerema N. A. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children’s Cancer Group. J. Clin. Oncol., 16: 527-535, 1998.[Abstract]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
V. I. Brown, J. Hulitt, J. Fish, C. Sheen, M. Bruno, Q. Xu, M. Carroll, J. Fang, D. Teachey, and S. A. Grupp
Thymic Stromal-Derived Lymphopoietin Induces Proliferation of Pre-B Leukemia and Antagonizes mTOR Inhibitors, Suggesting a Role for Interleukin-7R{alpha} Signaling
Cancer Res., October 15, 2007; 67(20): 9963 - 9970.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. T. Teachey, D. A. Obzut, K. Axsom, J. K. Choi, K. C. Goldsmith, J. Hall, J. Hulitt, C. S. Manno, J. M. Maris, N. Rhodin, et al.
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
Blood, September 15, 2006; 108(6): 1965 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. A. Zweidler-McKay, Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. Aster, D. Allman, and W. S. Pear
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies
Blood, December 1, 2005; 106(12): 3898 - 3906.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. I. Brown, J. Fang, K. Alcorn, R. Barr, J. M. Kim, R. Wasserman, and S. A. Grupp
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
PNAS, December 9, 2003; 100(25): 15113 - 15118.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J. M.
Right arrow Articles by Grupp, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J. M.
Right arrow Articles by Grupp, S. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online